<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03229187</url>
  </required_header>
  <id_info>
    <org_study_id>2016-NACT-01</org_study_id>
    <nct_id>NCT03229187</nct_id>
  </id_info>
  <brief_title>Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer</brief_title>
  <official_title>Accurate Prediction and Validation of Response to Neoadjuvant Chemotherapy in Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical cancer is one of the major health problems for chinese women. Besides surgery and
      radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many
      studies.

      However, not all patients respond well to neoadjuvant chemotherapy. Knowing the therapeutic
      effect of the neoadjuvant chemotherapy before receiving it can not only reduce the economic
      burden, but also more importantly save time to take more suitable treatments.

      This study is undertaken to build specific molecular signatures to predict the effects of
      neoadjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2016</start_date>
  <completion_date type="Anticipated">October 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>The clinical response to neoadjuvant chemotherapy</measure>
    <time_frame>1 to 3 months</time_frame>
    <description>clinical response（tumor size）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pathological response to neoadjuvant chemotherapy</measure>
    <time_frame>1 to 3 months</time_frame>
    <description>pathological response（&lt;3 mm or not）</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Cervical Cancer</condition>
  <condition>Uterine Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>neoadjuvant chemotherapy</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples with DNA from blood and tissues.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with histologically confirmed Ib~ IIb cervical carcinoma underwent Neoadjuvant
        Chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Untreated cervical cancer with FIGO stage Ib-IIb

          -  Measurable lesions

          -  Possible to radical hysterectomy

          -  Age: 18 and older

          -  Karnofsky Performance Status≥ 70.

          -  WBC &gt; 3,000/mm³, Hb &gt; 9.0g/dl, Platelet &gt; 100,000 /mm³, SGOT/SGPT &lt; 60 IU/L, T-Bil &lt;
             1.5 mg/dL, Cr &lt; 1.2 mg/dL, PaO2 &gt; 80 torr, normal ECG

          -  Written informed consent

        Exclusion Criteria:

          -  Previous history of cancer

          -  Patients with previous treatment

          -  Patients without information of clinical risk factors

          -  Patients who have active infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Ma Ding, M.D.</last_name>
    <phone>86-27-8362681</phone>
    <email>dma@tjh.tjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ma Ding, M.D.</last_name>
      <phone>86-27-8362681</phone>
      <email>dma@tjh.tjmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2017</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Ding Ma</investigator_full_name>
    <investigator_title>Director of Department of Gynecology and Obstetrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

